Peptic Ulcer
Conditions
Brief summary
The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.
Interventions
DRUGLanston Capsule 15 mg placebo
Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
DRUGJP-1366 10 mg
JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
DRUGLanston Capsule 15 mg
Lanston Capsule 15 mg orally once a day for up to 24 weeks
DRUGJP-1366 10 mg placebo
JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
Sponsors
Onconic Therapeutics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult male/female aged 19 years or older as of the date of obtaining consent 2. Those who are diagnosed with musculoskeletal diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, or other diseases at the time of screening and require continuous administration of NSAIDs for 24 weeks or more 3. Those with one or more of the following risk factors for ulcer development at the time of screening 4. Subjects who fully understand this study and voluntarily signed the informed consent form.
Exclusion criteria
1. Those who cannot undergo upper gastrointestinal endoscopy 2. At the time of screening, those who were confirmed to have active stage ulcers (A1, A2) or healing stage ulcers (H1, H2) in the stomach or duodenum according to the Sakita-Miwa Classification\* 3. Those with a confirmed history of malignant tumor within 5 years 4. Those with a confirmed history of signal symptoms suggestive of malignant disease of the gastrointestinal tract 5. Those who need to continuously take corticosteroids, antiplatelet agents, and anticoagulants during this study (however, the following cases are permitted): 6. Pregnant and lactating women or those with a positive pregnancy test result at screening 7. Those who participated in another study and were administered investigational products or had medical devices applied at least once within 4 weeks from the screening visit(Visit 0)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative proportion of subjects who developed peptic ulcers | at 24 weeks after administration of investigational products |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of subjects with gastric or duodenal endoscopic bleeding | at 24 weeks after administration of investigational products |
Countries
South Korea
Contacts
Primary ContactJohn KIM
Outcome results
None listed